Insulet Corp
NASDAQ:PODD
Insulet Corp
Free Cash Flow
Insulet Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insulet Corp
NASDAQ:PODD
|
Free Cash Flow
$296.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Free Cash Flow
$2.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Free Cash Flow
$2.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Free Cash Flow
$6.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Free Cash Flow
$586m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
What is Insulet Corp's Free Cash Flow?
Free Cash Flow
296.3m
USD
Based on the financial report for Dec 31, 2024, Insulet Corp's Free Cash Flow amounts to 296.3m USD.
What is Insulet Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
712%
Over the last year, the Free Cash Flow growth was 712%.
You don't have any saved screeners yet